AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
ArriVent BioPharma, Inc.
Video analysis: AVBP
All videosNo video analysis for this stock yet. Request one from our team.
News: AVBP
Deutsche Bank AG Acquires Shares of 39,180 ArriVent BioPharma, Inc. $AVBP
Deutsche Bank AG bought a new position in shares of ArriVent BioPharma, Inc. (NASDAQ: AVBP) in the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor bought 39,180 shares of the company's stock, valued at approximately $1,361,000. Deutsche Bank AG owned 0.08% of ArriVent BioPharma at the end
ArriVent BioPharma: Firmonertinib Delay Strengthens The Upside Case
The Firmonertinib readout moving to H2 2026 may signal slower event accumulation and longer progression-free survival. Firmonertinib remains the core value driver, with our base case assuming meaningful penetration across EGFR exon 20 insertion and PACC populations. Pipeline optionality is expanding, with ARR-217 entering Phase 1 and ARR-002 approaching first-patient dosing.
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Shares of ArriVent BioPharma, Inc. (NASDAQ: AVBP - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the ten analysts that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy
Dimensional Fund Advisors LP Has $2.92 Million Stock Holdings in ArriVent BioPharma, Inc. $AVBP
Dimensional Fund Advisors LP lifted its stake in shares of ArriVent BioPharma, Inc. (NASDAQ: AVBP) by 758.2% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 126,525 shares of the company's stock after acquiring an additional 111,782 shares during the
ArriVent BioPharma Reports Second Quarter 2026 Financial Results
NEWTOWN SQUARE, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent Company progress.
Affinity Asset Advisors LLC Purchases 25,000 Shares of ArriVent BioPharma, Inc. $AVBP
Affinity Asset Advisors LLC lifted its position in shares of ArriVent BioPharma, Inc. (NASDAQ: AVBP) by 16.7% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 175,000 shares of the company's stock after purchasing an additional 25,000 shares during the
